Developing Univariate Neurodegeneration Biomarkers with Low-Rank and Sparse Subspace Decomposition

TL;DR

This paper introduces a novel low-rank and sparse subspace decomposition method to develop univariate neurodegeneration biomarkers from sMRI data, effectively capturing AD-related morphological changes and outperforming traditional measures.

Contribution

The study proposes a new low-rank and sparse subspace decomposition approach for robustly quantifying AD-induced brain changes and constructing effective univariate biomarkers from hippocampal features.

Findings

UMIs require fewer samples to detect changes compared to traditional measures.

UMIs correlate with conversion risk to AD within 18 months.

Our method outperforms hippocampal volume measures in detecting neurodegeneration.

Abstract

Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration biomarkers (UNB). However, existing UNB work either fails to model large group variances or does not capture AD dementia (ADD) induced changes. We propose a novel low-rank and sparse subspace decomposition method capable of stably quantifying the morphological changes induced by ADD. Specifically, we propose a numerically efficient rank minimization mechanism to extract group common structure and impose regularization constraints to encode the original 3D morphometry connectivity. Further, we generate regions-of-interest (ROI) with group difference study between common subspaces of $A\beta+$ AD and $A\beta-$ cognitively unimpaired (CU) groups. A univariate morphometry index (UMI) is constructed from these ROIs by summarizing individual morphological characteristics weighted by normalized difference between $A\beta+$ AD and $A\beta-$ CU groups. We use hippocampal surface radial distance feature to compute the UMIs and validate our work in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. With hippocampal UMIs, the estimated minimum sample sizes needed to detect a 25$\%$ reduction in the mean annual change with 80$\%$ power and two-tailed $P=0.05$ are 116, 279 and 387 for the longitudinal $A\beta+$ AD, $A\beta+$ mild cognitive impairment (MCI) and $A\beta+$ CU groups, respectively. Additionally, for MCI patients, UMIs well correlate with hazard ratio of conversion to AD ($4.3$, $95\%$ CI=$2.3-8.2$) within 18 months. Our experimental results outperform traditional hippocampal volume measures and suggest the application of UMI as a potential UNB.